GLG News by Pharmacists (US)

Dangers of over-medication.  Lack of long term studies.  lack of personal and parental responsibility

To enhance health care efficiency, MDs should not have to purchase and stock expensive biotech drugs in their office.  Drugs should be charged to the health plan or PBM and the drugs should arrive at the MDs office labeled for the particular patient

Pricing constraints in the US such as Best Price legislation preclude innovative outcomes based solutions from being adopted.  CMS should provide waivers to Best Price to enable payers and drug innovators to engage in risk based contracts

Drugs are released to the market without adequate study, then, after around 70 to 100 patient deaths due to the drug are reported, the drug is pulled from the market.  Getting in front of this "problem" would improve the safety of our drug supply.

Drug company (Roche) retaliates against an agency that speaks the truth about their chemical - that it's cost is not worth the minimal benefit.  This will become more common as time goes on, even here in the bastion of capitalism.

Keep the stuff refrigerated.

Antipsychotic drugs have been shown to increase morbidity and mortality in demented patients.  These agents are used to keep patients calm and easy to manipulate because there is not enough nursing home staff to adequately care for patients mental and physical needs.  "Chemical straight-jackets",...

For the right patient, epoietin products can make a world of difference in quality of life.  For the wrong patient, the drugs can cause clotting and can be fatal.  (I was involved with a patient's care once who died from a PE due to epoietin.  She had a hematocrit of 55% when she died.) ...

Another agent that lowers HBA1C by 0.02% is not a big deal.  There are already too many of these products on the market, none of which do much of anything to improve diabetes care. 

The evidence for this idea was shaky to begin with.  I'm not surprised that it  was finally debunked.